Today's regulatory highlight is not a drug approval but a pharmacogenomic guideline with direct otological consequences. Mitochondrial MT-RNR1 variants (m.1555A>G and others), carried by roughly 1 in 330 people, cause irreversible sensorineural hearing loss after aminoglycoside exposure — sometimes after a single dose, at ordinary therapeutic levels.
The UK guideline recommends avoiding aminoglycosides at any detectable variant. In England, laboratory MT-RNR1 testing is nationally commissioned, and point-of-care testing is used in some centres for time-critical settings such as neonatal sepsis; around 20% of aminoglycoside use is predictable enough to test pre-emptively. Crucially, where a result is not available and the clinical need is urgent, treatment should not be delayed.
For ENT this matters twice: as the specialty that sees the resulting deafness, and as advisers on aminoglycoside use, including topical drops in some contexts. Know whether your service can access testing, and flag a family history of aminoglycoside-associated hearing loss as a reason to test or avoid.
- MT-RNR1 variants (~1 in 330) cause irreversible hearing loss after aminoglycosides, sometimes from one dose
- Guideline: avoid aminoglycosides at any detectable variant
- Testing is nationally commissioned in England; ~20% of use is predictable and testable
- Do not delay urgent aminoglycoside treatment when a result is unavailable
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ent & head and neck surgery, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free